Safety and Protective Efficacy of FF-3 Dry Powder in Healthy Subjects Infected With Influenza Challenge Strain
Phase 2
Completed
- Conditions
- Influenza
- Interventions
- Drug: FF-3 dry powderDrug: Placebo
- First Posted Date
- 2015-04-22
- Last Posted Date
- 2017-08-14
- Lead Sponsor
- Autoimmune Technologies, LLC
- Target Recruit Count
- 79
- Registration Number
- NCT02423577
- Locations
- 🇬🇧
Quintiles Drug Research Unit, London, United Kingdom
Safety, Tolerability, and PK of Escalating Doses of Flufirvitide-3 Dry Powder for Inhalation in Healthy Subjects
Phase 1
Completed
- Conditions
- Influenza
- Interventions
- Drug: Placebo for Flufirvitide-3
- First Posted Date
- 2013-11-25
- Last Posted Date
- 2015-03-11
- Lead Sponsor
- Autoimmune Technologies, LLC
- Target Recruit Count
- 68
- Registration Number
- NCT01990846
- Locations
- 🇺🇸
Spartanburg Medical Research, Spartanburg, South Carolina, United States
Safety Study of Flufirvitide-3 Nasal Spray in Healthy Subjects
Phase 1
Completed
- Conditions
- Influenza
- Interventions
- Drug: Flufirvitide-3 0.05 mg single doseOther: PlaceboDrug: Flufirvitide-3, 0.1 mg single doseDrug: Flufirvitide-3, 0.2 mg single doseDrug: Flufirvitide-3, 0.4 mg single dose
- First Posted Date
- 2011-03-14
- Last Posted Date
- 2012-01-16
- Lead Sponsor
- Autoimmune Technologies, LLC
- Target Recruit Count
- 32
- Registration Number
- NCT01313962
- Locations
- 🇺🇸
Quintiles Phase One Services, Overland Park, Kansas, United States
© Copyright 2025. All Rights Reserved by MedPath